Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.
Chen YW, Tucker MD, Brown LC, Yasin HA, Ancell KK, Armstrong AJ, Beckermann KE, Davis NB, Harrison MR, Kaiser EG, McAlister RK, Schaffer KR, Wallace DE, George DJ, Rathmell WK, Rini BI, Zhang T. Chen YW, et al. Among authors: rathmell wk. Cancers (Basel). 2022 Aug 7;14(15):3830. doi: 10.3390/cancers14153830. Cancers (Basel). 2022. PMID: 35954493 Free PMC article.
Renal cell carcinoma.
Rathmell WK, Godley PA, Rini BI. Rathmell WK, et al. Curr Opin Oncol. 2005 May;17(3):261-7. doi: 10.1097/01.cco.0000155007.51495.d6. Curr Opin Oncol. 2005. PMID: 15818172 Review.
Molecularly targeted therapy in renal cell carcinoma.
Rathmell WK, Wright TM, Rini BI. Rathmell WK, et al. Expert Rev Anticancer Ther. 2005 Dec;5(6):1031-40. doi: 10.1586/14737140.5.6.1031. Expert Rev Anticancer Ther. 2005. PMID: 16336094 Review.
Renal cell carcinoma.
Rini BI, Campbell SC, Rathmell WK. Rini BI, et al. Among authors: rathmell wk. Curr Opin Oncol. 2006 May;18(3):289-96. doi: 10.1097/01.cco.0000219260.60714.c4. Curr Opin Oncol. 2006. PMID: 16552243 Review.
Renal cell carcinoma.
Rathmell WK, Martz CA, Rini BI. Rathmell WK, et al. Curr Opin Oncol. 2007 May;19(3):234-40. doi: 10.1097/CCO.0b013e3280ad4388. Curr Opin Oncol. 2007. PMID: 17414642 Review.
Renal cell carcinoma.
Rini BI, Rathmell WK, Godley P. Rini BI, et al. Among authors: rathmell wk. Curr Opin Oncol. 2008 May;20(3):300-6. doi: 10.1097/CCO.0b013e3282f9782b. Curr Opin Oncol. 2008. PMID: 18391630 Review.
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.
Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ. Whang YE, et al. Among authors: rathmell wk. Urol Oncol. 2013 Jan;31(1):82-6. doi: 10.1016/j.urolonc.2010.09.018. Epub 2011 Mar 10. Urol Oncol. 2013. PMID: 21396844 Clinical Trial.
State of the science: an update on renal cell carcinoma.
Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. Jonasch E, et al. Among authors: rathmell wk. Mol Cancer Res. 2012 Jul;10(7):859-80. doi: 10.1158/1541-7786.MCR-12-0117. Epub 2012 May 25. Mol Cancer Res. 2012. PMID: 22638109 Free PMC article. Review.
304 results